Innovation is driven through a strong digital backbone.
Pharmaceutical Technology's In the Lab eNewsletter, September 2022
An integrated approach to the data lifecycle is key to successful digital transformation.
Bio-Rad’s new antibodies are designed to develop highly selective pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars.
Roche’s Digital LightCycler System is designed to aid in diagnostics for cancer, genetic disease, and infection.
Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.
Canvax’s new inorganic pyrophosphate is designed for in-vitro transcription reactions.
CYTENA’s B.SIGHT cell dispenser is designed to streamline single-cell isolation in microbiology research.
The Faustovirus Capping Enzyme launched by New England Biolabs is designed to increase capping efficiency and scalability of mRNA manufacturing workflows.
Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Audits, Inspections, and CDMOs
2
Ready or Not: Biopharma Alignment for CNPV’s Rapid Review
3
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two
4
FAQ: Everything to Know About Excipients in the Digital Era
5
